98%
921
2 minutes
20
Recently, miraculous therapy approaches involving adeno-associated virus (AAV) for incurable diseases such as spinal muscular atrophy and inherited retinal dysfunction have been introduced. Nonreplicative, nonpathogenic, low rates of chromosome insertional properties and the existence of neutralizing antibodies are main safety reasons why the FDA approved its use in gene delivery. To date, AAV production always results in a mixture of nontherapeutic (empty) and therapeutic (DNA-loaded) full capsids (10-98%). Such existence of empty viral particles inevitably increases viral doses to human. Thus, the rapid monitoring of empty capsids and reducing the empty-to-full ratio are critical in AAV science. However, transmission electron microscopy (TEM) is the primary tool for distinguishing between empty and full capsids, which creates a research bottleneck because of instrument accessibility and technical difficulty. Herein, we demonstrate that atomic force microscopy (AFM) can be an alternative tool to TEM. The simple, noncontact-mode imaging of AAV particles allows the distinct height difference between full capsids (∼22 nm) and empty capsids (∼16 nm). The sphere-to-ellipsoidal morphological distortion observed for empty AAV particles clearly distinguishes them from full AAV particles. Our study indicates that AFM imaging can be an extremely useful, quality-control tool in AAV particle monitoring, which is beneficial for the future development of AAV-based gene therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.langmuir.3c00241 | DOI Listing |
J Chromatogr A
October 2025
Tosoh Bioscience LLC, 3604 Horizon Drive, King of Prussia, PA 19406, USA. Electronic address:
Recombinant adeno-associated virus (AAV) vectors have emerged as powerful gene delivery tools for the treatment of genetic disorders. However, the production of high-quality AAV vectors still poses significant challenges. In upstream manufacturing, AAV genome packaging typically results in a diverse pool of empty and partially filled capsids, as well as the desired functional virions.
View Article and Find Full Text PDFBiotechnol Bioeng
August 2025
BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, Massachusetts, USA.
Adeno-associated virus (AAV) is one of the most common delivery systems used in gene therapy. Challenges in the development and manufacturing of AAVs include high cost of goods (COGs) per dose, process scalability, speed to market, and process-related impurities such as empty capsids. This article presents a streamlined approach to developing and scaling AAV upstream production process via triple transfection from bench scale to commercial volumes exceeding 1,000 L.
View Article and Find Full Text PDFJ Virol
August 2025
Department of Microbiology and Immunology, University of Otago, Dunedin, Otago, New Zealand.
Picornavirus cell entry requires a series of capsid protein conformational changes leading to genome uncoating. For enteroviruses, receptor binding triggers the transition from a full (F) capsid to an altered (A) particle before releasing its genome and finally converting it into an empty (E) particle. In contrast, non-enteroviruses, such as Aphthovirus, Cardiovirus, or Seneca Valley virus, release their genomes by dissociating the capsid into pentamers.
View Article and Find Full Text PDFAnal Chim Acta
October 2025
School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland. Electronic address:
Background: Recombinant adeno-associated virus (rAAV) vectors have emerged as a leading platform for gene therapy, supported by several FDA-approved products and numerous clinical trials. Due to their biological complexity and heterogeneity, rigorous analytical methods are essential to ensure the quality, safety, and efficacy of rAAV-based products. Critical quality attributes (CQAs) such as aggregation, full/empty capsid ratios, viral protein composition, and post-translational modifications (PTMs) must be monitored comprehensively.
View Article and Find Full Text PDFPLoS Pathog
August 2025
Institute for Molecular Virology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Parvoviruses are single-stranded DNA viruses that have been modified to serve as vehicles for therapeutic transgene delivery in the form of recombinant Adeno-Associated Virus (rAAV2) vectors or rodent parvovirus-derived oncolytic agents. Infection with viruses of the Parvoviridae family induces a cellular DNA Damage Response (DDR) signal that supports virus replication. However, it remains unknown whether rAAV2 vectors or non-replicative wild-type AAV2 (wtAAV2) genomes induce cellular DDR signals, which might be deleterious to the cell.
View Article and Find Full Text PDF